



(12) Translation of
european patent specification

(11) NO/EP 2275443 B1

NORWAY

(19) NO
(51) Int Cl.
C07K 16/28 (2006.01)
A61K 39/00 (2006.01)
C07K 16/24 (2006.01)
C12N 15/10 (2006.01)
G01N 33/68 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2016.04.04
(80)	Date of The European Patent Office Publication of the Granted Patent	2015.12.02
(86)	European Application Nr.	09729337.7
(86)	European Filing Date	2009.04.10
(87)	The European Application's Publication Date	2011.01.19
(30)	Priority	2008.04.11, JP, 2008104147 2008.09.26, JP, 2008247713 2009.03.19, JP, 2009068744
(84)	Designated Contracting States:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR
	Designated Extension States:	AL BA RS
(73)	Proprietor	Chugai Seiyaku Kabushiki Kaisha, 5-1, Ukima 5-chome, Kita-ku, Tokyo 115-8543, JP-Japan
(72)	Inventor	IGAWA, Tomoyuki, c/o Chugai Seiyaku Kabushiki Kaisha, 135 Komakado 1-chome, Gotenba-shi, Shizuoka 412-8513, JP-Japan ISHII, Shinya, c/o Chugai Seiyaku Kabushiki Kaisha, 135 Komakado 1-chome, Gotenba-shi, Shizuoka 412-8513, JP-Japan MAEDA, Atsuhiko, c/o Chugai Seiyaku Kabushiki Kaisha, 135 Komakado 1-chome, Gotenba-shi, Shizuoka 412-8513, JP-Japan NAKAI, Takashi, c/o Chugai Seiyaku Kabushiki Kaisha, 135 Komakado 1-chome, Gotenba-shi, Shizuoka 412-8513, JP-Japan
(74)	Agent or Attorney	Zacco Norway AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54)	Title	ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO TWO OR MORE ANTIGEN MOLECULES REPEATEDLY
(56)	References Cited:	WO-A1-2009/139822 WO-A2-2011/111007 US-A1- 2003 059 937 MAEDA K ET AL: "pH-dependent receptor/ligand dissociation as a determining factor for intracellular sorting of ligands for epidermal growth factor receptors in rat hepatocytes", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 82, no. 1, 18 July 2002 (2002-07-18), pages 71-82, XP004369791, ISSN: 0168-3659, DOI: 10.1016/S0168-3659(02)00126-8 FREDERICK R MAXFIELD & TIMOTHY E MCGRAW: "Endocytic recycling", NATURE REVIEWS MOLECULAR CELL BIOLOGY, NATURE PUBLISHING, GB, vol. 5, no. 2, 1 February 2004 (2004-02-01), pages 121-132, XP009151548, ISSN: 1471-0072

MEGAN L. MURTAUGH ET AL: "A combinatorial histidine scanning library approach to engineer highly pH-dependent protein switches", PROTEIN SCIENCE, vol. 20, no. 9, 1 September 2011 (2011-09-01), pages 1619-1631, XP055011183, ISSN: 0961-8368, DOI: 10.1002/pro.696

IGAWA T ET AL: "Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 28, no. 11, 1 November 2010 (2010-11-01), pages 1203-1207, XP009153598, ISSN: 1087-0156, DOI: 10.1038/NBT.1691

T. IGAWA ET AL: "Reduced elimination of IgG antibodies by engineering the variable region", PROTEIN ENGINEERING DESIGN AND SELECTION, vol. 23, no. 5, 1 May 2010 (2010-05-01), pages 385-392, XP055003115, ISSN: 1741-0126, DOI: 10.1093/protein/gzq009

IGAWA TOMOYUKI ET AL: "Engineering the variable region of therapeutic IgG antibodies", MABS, LANDES BIOSCIENCE, US, vol. 3, no. 3, 1 May 2011 (2011-05-01), pages 243-252, XP009153597, ISSN: 1942-0870

ITO W ET AL: "The His-probe method: effects of histidine residues introduced into the complementary-determining regions of antibodies on antigen-antibody interactions at different pH values", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 309, no. 1, 1 August 1992 (1992-08-01), pages 85-88, XP008123385, ISSN: 0014-5793

ITO, W. ET AL.: 'The His-probe method: effects of histidine residues introduced into the complementarity-determining regions of antibodies on antigen-antibody interactions at different pH values.' FEBS LETT. vol. 309, no. 1, 1992, pages 85 - 88, XP008123385

MARTIN, W.L. ET AL.: 'Crystal Structure at 2.8Å of an FcRn/Heterodimeric Fc Complex: Mechanism of pH-Dependent Binding.' MOL.CELL. vol. 7, 2001, pages 867 - 877, XP003027710

TETSUO K ET AL: "A monoclonal antibody specific for a distinct region of hen egg-white lysozyme", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 19, no. 4, 1 April 1982 (1982-04-01), pages 619-630, XP023681027, ISSN: 0161-5890, DOI: 10.1016/0161-5890(82)90231-0 [retrieved on 1982-04-01]

RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 79, 1 March 1982 (1982-03-01), pages 1979-1983, XP007901436, ISSN: 0027-8424, DOI: 10.1073/PNAS.79.6.1979

Bassett ET AL: "STUDIES ON HUMAN ANTIBODIES. 3. AMINO ACID COMPOSITION OF FOUR ANTIBODIES FROM ONE INDIVIDUAL.", Journal of Experimental Medicine, vol. 122, 1 August 1965 (1965-08-01), pages 251-261, XP055057759, ISSN: 0022-1007

Rebecca L. Rich ET AL: "Grading the commercial optical biosensor literature-Class of 2008: 'The Mighty Binders'", Journal of Molecular Recognition, vol. 23, no. 1, 16 January 2010 (2010-01-16), pages 1-64, XP55064620, ISSN: 0952-3499, DOI: 10.1002/jmr.1004

YANG W-P ET AL: "CDR WALKING MUTAGENESIS FOR THE AFFINITY MATURATION OF A POTENT HUMAN ANTI-HIV-1 ANTIBODY INTO THE PICOMOLAR RANGE", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 254, 1 January 1995 (1995-01-01), pages 392-403, XP000199739, ISSN: 0022-2836, DOI: 10.1006/JMBI.1995.0626

Andrew W Drake ET AL: "Biophysical Consideration for Development of Antibody-Based Therapeutics" In: "Biophysical Consideration for Development of Antibody-Based Therapeutics", 1 January 2012 (2012-01-01), XP055100977, pages 95-97,

LEE C V ET AL: "High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 340, no. 5, 23 July 2004 (2004-07-23) , pages 1073-1093, XP002716293, ISSN: 0022-2836, DOI: 10.1016/J.JMB.2004.05.051

CASIM A SARKAR ET AL: "Rational cytokine design for increased lifetime and enhanced potency using pH-activated histidine switching", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 20, no. 9, 1 September 2002 (2002-09-01), pages 908-913, XP002657852, ISSN: 1087-0156, DOI: 10.1038/NBT725 [retrieved on 2002-08-05]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

5 **1.** Fremgangsmåte for å bedre et antistoffs farmakokinetikk, der fremgangsmåten omfatter å substituere minst én aminosyre i et antistoffs CDR med en histidin, eller innføre minst én histidin i antistoffets CDR, hvori histidinsubstitusjonen eller -innføringen øker $KD(pH5,8)/KD(pH7,4)$ -verdien sammenlignet med $KD(pH5,8)/KD(pH7,4)$ -verdien før histidinsubstitusjonen eller innføringen, hvori $KD(pH5,8)/KD(pH7,4)$ -verdien er definert som forholdet til antigenbindingsaktiviteten ved pH 5,8 og antigenbindingsaktiviteten ved pH 7,4, 10 og hvori histidinsubstitusjonen eller innføringen

(a) forlenger halveringstiden i plasma eller den gjennomsnittlige plasmaretensjonstiden til antistoffet; eller

(b) øker antallet ganger for antigenbinding for antistoffet, der økningen korresponderer med en økning i antallet sykluser som antistoffet bundet av et 15 antigen, internaliseres inn i en celle og frigis i en antigenfri form til utsiden av cellen.

20 **2.** Fremgangsmåten ifølge krav 1, hvori $KD(pH5,8)/KD(pH7,4)$ -verdien etter histidinsubstitusjon eller innføring er 2 eller høyere, 10 eller høyere eller 40 eller høyere.